Primary Ciliary Dyskinesia Market Gearing Up for Outstanding Expansion During the Forecast Period (2023-32) | Parion Sciences, Vertex Pharmaceuticals, ReCode Therapeutics, Aerocrine AB, CEISO
DelveInsight’s “Primary Ciliary Dyskinesia Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Primary Ciliary Dyskinesia market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Primary Ciliary Dyskinesia drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Primary Ciliary Dyskinesia treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Primary Ciliary Dyskinesia: An Overview
Primary Ciliary Dyskinesia (PCD) is usually an autosomal recessive genetic condition in which the microscopic organelles (cilia) in the respiratory system have defective function. Ciliary dysfunction prevents the clearance of mucous from the lungs, paranasal sinuses, and middle ears. Bacteria and other irritants in the mucous lead to frequent respiratory infections.
Symptoms often begin shortly after birth and can include coughing, gagging, choking, and lung atelectasis (neonatal respiratory distress). Affected individuals often experience chronic sinus, middle ear, and lung infections as well as chronic coughing, excess mucus, and hearing loss.
Primary Ciliary Dyskinesia is diagnosed definitively by examining lung or sinus tissue obtained from a biopsy or through genetic testing. Specific structural defects that are present in these tissues can be detected under an electron microscope. Airway clearance therapy is used to keep the lung tissue healthy for as long as possible. This therapy may include routine washing and suctioning of the sinus cavities and ear canals. Antibiotics, bronchodilators, steroids, and mucus thinners (mucolytics) are also used to treat Primary Ciliary Dyskinesia.
Primary Ciliary Dyskinesia Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Primary Ciliary Dyskinesia pipeline therapies. It also thoroughly assesses the Primary Ciliary Dyskinesia market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the market trend for each marketed Primary Ciliary Dyskinesia drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Primary Ciliary Dyskinesia Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Primary Ciliary Dyskinesia epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Primary Ciliary Dyskinesia epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
Primary Ciliary Dyskinesia Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Primary Ciliary Dyskinesia market or expected to be launched during the study period. The analysis covers the Primary Ciliary Dyskinesia market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Primary Ciliary Dyskinesia drugs based on their sale and market share.
The report also covers the Primary Ciliary Dyskinesia pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Primary Ciliary Dyskinesia companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Primary Ciliary Dyskinesia Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/primary-ciliary-dyskinesia-market
Recent Developmental Activities in the Treatment Landscape
-
On March 2023, ReCode Therapeutics announced a study of phase 1 clinical trials for RCT1100. This study with RCT1100 marks the first time it is being conducted in humans. Its primary objective is to gather preliminary safety and tolerability data, which will be crucial for guiding future clinical investigations.
Primary Ciliary Dyskinesia Therapeutics Analysis
Several major pharma and biotech companies are developing therapies for Primary Ciliary Dyskinesia. Currently, Parion Sciences is leading the therapeutic market with its Primary Ciliary Dyskinesia drug candidates in the most advanced stage of clinical development.
Primary Ciliary Dyskinesia Companies Actively Working in the Therapeutics Market Include
-
Parion Sciences
-
Vertex Pharmaceuticals
-
ReCode Therapeutics
-
Aerocrine AB
-
CEISO
And Many Others
Emerging and Marketed Primary Ciliary Dyskinesia Therapies Covered in the Report Include:
-
P 1037: Parion Sciences
Epithelial sodium channel (ENaC) inhibitors are designed to block the sodium channels on the airway surfaces. In pulmonary diseases, such as chronic obstructive pulmonary disease, cystic fibrosis, and Primary Ciliary Dyskinesia, where there is a build-up of excessively concentrated mucus, preclinical models have demonstrated that blocking ENaC hydrates the mucus on the lung surface. Hydration of airway mucus restores airway clearance and improves lung function. P-1037 is a novel, long-acting ENaC Inhibitor that was well tolerated at the doses tested in multiple clinical trials in healthy volunteers and patients with either cystic fibrosis or Primary Ciliary Dyskinesia.
The Report Covers an In-depth Assessment of Emerging Drugs and key Companies. Download the Sample Report to Learn More @
https://www.delveinsight.com/sample-request/primary-ciliary-dyskinesia-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Primary Ciliary Dyskinesia Competitive Intelligence Analysis
4. Primary Ciliary Dyskinesia Market Overview at a Glance
5. Primary Ciliary Dyskinesia Disease Background and Overview
6. Primary Ciliary Dyskinesia Patient Journey
7. Primary Ciliary Dyskinesia Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Primary Ciliary Dyskinesia Treatment Algorithm, Current Treatment, and Medical Practices
9. Primary Ciliary Dyskinesia Unmet Needs
10. Key Endpoints of Primary Ciliary Dyskinesia Treatment
11. Primary Ciliary Dyskinesia Marketed Therapies
12. Primary Ciliary Dyskinesia Emerging Drugs and Latest Therapeutic Advances
13. Primary Ciliary Dyskinesia Seven Major Market Analysis
14. Attribute Analysis
15. Primary Ciliary Dyskinesia Market Outlook (In US, EU5, and Japan)
16. Primary Ciliary Dyskinesia Companies Active in the Market
17. Primary Ciliary Dyskinesia Access and Reimbursement Overview
18. KOL Views on the Primary Ciliary Dyskinesia Market
19. Primary Ciliary Dyskinesia Market Drivers
20. Primary Ciliary Dyskinesia Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/primary-ciliary-dyskinesia-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Emphysema Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Emphysema market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Emphysema market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/medical-devices
 | Parion Sciences, Vertex Pharmaceuticals, ReCode Therapeutics, Aerocrine AB, CEISO){kind=link}